Abstract:Background: This study demonstrates the preclinical evaluation of a novel 4-1BB/CD24 bispecific antibody IBD0333. 4-1BB's activation triggers a signaling cascade that activates both innate and adaptive immune systems. Due to the hepatotoxicity of current anti-4-1BB monoclonal antibodies, tumor-associated antigens (TAA) targeting to specifically activate immune cells in the tumor microenvironment (TME) is expected to enhance its safety profile. CD24 is highly expressed in many cancers, such as ovarian and breast cancer and its high expression is often related to poor prognosis. The signaling pathway of CD24/Siglec-10 triggers a "don't eat me" signal that facilitates immune escape of tumor cells. Therefore, IBD0333 was designed to target CD24 overexpressed tumor cells and activate CD8+ T cells to induce T cell mediated antitumor immunity in TME of the targeted tumor tissue. To further reduce the toxicity risk, the anti-4-1BB moiety is designed to activate the signaling pathway only when IBD0333 binds to the tumor cells that overexpress CD24. Methods: For CD24 terminus, we applied virus like particle (VLP) as antigen for immunization to obtain functional CD24 antibodies. For 4-1BB terminus, competitive ELISA/FACS analysis as well as amino acid point mutation binding ability analysis based on the receptor crystal structure were performed to characterize the binding epitope. The in vivo mice efficacy and toxicity study, as well as cynomolgus monkey toxicity study were also conducted to describe the anti-tumor activity and safety profile. For IBD0333, we verified binding affinity by FACS to cancer cells and the 4-1BB activity in reporter-gene assay. IL2 and INF-γ secretion assay were performed to evaluate the PBMC activation. C57BL/6J-h4-1BB humanized mice bearing MC38-hCD24 colon cancer cells were used to validate the anti-tumor efficacy of IBD0333. Preclinical PK and toxicity study was also performed in cynomolgus monkeys to describe the safety profile of IBD0333. Results: IBD0333 showed excellent binding and PBMC stimulation activities. In toxicology studies of IBD0333, no obvious abnormality in mice or cynomolgus monkeys administered with IBD0333 was observed. The MTD was estimated to be greater than 200 mg/kg with no severe side effects observed in the study, showing that IBD0333 has great potential to achieve significantly improved safety profile. As to efficacy, IBD0333 showed excellent tumor inhibition activities in mice model with 99% tumor growth inhibition at 1 mg/kg and 100% at 3 mg/kg. Conclusion: IBD0333 is a clinical stage, potential first-in-class, 4-1BB/CD24 bsAb that simultaneously stimulates both innate and adaptive immunity to achieve strong synergistic effects with reduced hepatotoxicity. The IND approvals from the FDA and the NMPA have been obtained and the Phase I clinical trial of IBD0333 in locally advanced/metastatic solid tumors or non-Hodgkin's lymphoma is currently on-going. Citation Format: Xiaoling Jiang, Chongbing Wu, Zi Chen, Liusong Yin. Preclinical evaluation of a potential FIC 4-1BB/CD24 bispecific antibody IBD0333 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5307.

Safety and Efficacy of IBI389, an Anti-Cldn18.2/cd3 Bispecific Antibody, in Patients with Advanced Pancreatic Ductal Adenocarcinoma: Preliminary Results from a Phase 1 Study.

Safety and Efficacy of IBI343 (Anti-Claudin18.2 Antibody-Drug Conjugate) in Patients with Advanced Pancreatic Ductal Adenocarcinoma or Biliary Tract Cancer: Preliminary Results from a Phase 1 Study.

Phase I Study of the Efficacy and Safety of IBI319 in Patients with Advanced Malignant Tumors.

Phase Ia Dose Escalation of IBI318, a First-in-class Bispecific Anti-Pd-1/pd-l1, in Patients with Advanced Tumors.

Abstract CT513: Phase I Study of IBI322 (Anti-Cd47/pd-l1 Bispecific Antibody) Monotherapy Therapy in Patients with Advanced Solid Tumors in China

Preliminary Results of a Phase 1/2, First-in-human, Open-Label, Dose Escalation Study of ZL-1211 (Anti-Claudin 18.2 Mab) in Patients with Unresectable or Metastatic Solid Tumors

A Phase II, Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of YH003 in Combination with Toripalimab (Anti-Pd-1 Mab) in Patients with Unresectable/metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

Abstract 5307: Preclinical evaluation of a potential FIC 4-1BB/CD24 bispecific antibody IBD0333

A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti-Cldn18.2 Monoclonal Antibody, As Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors.

Efficacy and Safety of IBI110 in Combination with Sintilimab in First-Line Advanced HER2negative Gastric Cancer or Gastroesophageal Junction Cancer: Updated Results from a Phase Ib Study

BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.

Abstract LB057: Pre-clinical characterization of IBI343, a site-specifically conjugated anti-Claundin18.2 ADC, for treating solid tumors

Interim Results of a First-in-human Phase 1 Study of Q-1802, a CLDN18.2/PD-L1 Bsabs, in Patients with Relapsed or Refractory Solid Tumors.

Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study.

First-in-class PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 in Patients with Advanced Melanoma: Safety and Efficacy Results from a Phase I Study

Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.

Abstract B028: Claudin-18 expression (using the 43-14A antibody kit) in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for immunotherapy with zolbetuximab

Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.

Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial.

CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer

Abstract CT185: A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BC3402 in advanced solid malignancies